Your browser doesn't support javascript.
loading
Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder.
Lee, Brendan; Diaz, George A; Rhead, William; Lichter-Konecki, Uta; Feigenbaum, Annette; Berry, Susan A; Le Mons, Cindy; Bartley, James A; Longo, Nicola; Nagamani, Sandesh C; Berquist, William; Gallagher, Renata; Bartholomew, Dennis; Harding, Cary O; Korson, Mark S; McCandless, Shawn E; Smith, Wendy; Cederbaum, Stephen; Wong, Derek; Merritt, J Lawrence; Schulze, Andreas; Vockley, Jerry; Vockley, Gerard; Kronn, David; Zori, Roberto; Summar, Marshall; Milikien, Douglas A; Marino, Miguel; Coakley, Dion F; Mokhtarani, Masoud; Scharschmidt, Bruce F.
Afiliación
  • Lee B; 1] Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA [2] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
  • Diaz GA; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Rhead W; The Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Lichter-Konecki U; Children's National Medical Center, Washington, DC, USA.
  • Feigenbaum A; The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Berry SA; University of Minnesota, Minneapolis, Minnesota, USA.
  • Le Mons C; National Urea Cycle Disorders Foundation, Pasadena, California, USA.
  • Bartley JA; Miller Children's Hospital, Long Beach, California, USA.
  • Longo N; University of Utah, Salt Lake City, Utah, USA.
  • Nagamani SC; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
  • Berquist W; Stanford University, Palo Alto, California, USA.
  • Gallagher R; Children's Hospital Colorado, Aurora, Colorado, USA.
  • Bartholomew D; Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Harding CO; Oregon Health & Science University, Portland, Oregon, USA.
  • Korson MS; Tufts Medical Center, Boston, Massachusetts, USA.
  • McCandless SE; University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
  • Smith W; Maine Medical Center, Portland, Maine, USA.
  • Cederbaum S; University of California, Los Angeles, Los Angeles, California, USA.
  • Wong D; University of California, Los Angeles, Los Angeles, California, USA.
  • Merritt JL; University of Washington, Seattle, Washington, USA.
  • Schulze A; The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Vockley G; University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Kronn D; Westchester Medical Center, Westchester, New York, USA.
  • Zori R; University of Florida, Gainesville, Florida, USA.
  • Summar M; Children's National Medical Center, Washington, DC, USA.
  • Milikien DA; Accudata Solutions, Lafayette, California, USA.
  • Marino M; Tufts Medical Center, Boston, Massachusetts, USA.
  • Coakley DF; Hyperion Therapeutics, Brisbane, California, USA.
  • Mokhtarani M; Hyperion Therapeutics, Brisbane, California, USA.
  • Scharschmidt BF; Hyperion Therapeutics, Brisbane, California, USA.
Genet Med ; 17(7): 561-8, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25503497
PURPOSE: The aim of this study was to examine predictors of ammonia exposure and hyperammonemic crises in patients with urea cycle disorders. METHODS: The relationships between fasting ammonia, daily ammonia exposure, and hyperammonemic crises were analyzed in >100 patients with urea cycle disorders. RESULTS: Fasting ammonia correlated strongly with daily ammonia exposure (r = 0.764; P < 0.001). For patients with fasting ammonia concentrations <0.5 upper limit of normal (ULN), 0.5 to <1.0 ULN, and ≥1.0 ULN, the probability of a normal average daily ammonia value was 87, 60, and 39%, respectively, and 10.3, 14.1, and 37.0% of these patients, respectively, experienced ≥1 hyperammonemic crisis over 12 months. Time to first hyperammonemic crisis was shorter (P = 0.008) and relative risk (4.5×; P = 0.011) and rate (~5×, P = 0.006) of hyperammonemic crises were higher in patients with fasting ammonia ≥1.0 ULN vs. <0.5ULN; relative risk was even greater (20×; P = 0.009) in patients ≥6 years old. A 10- or 25-µmol/l increase in ammonia exposure increased the relative risk of a hyperammonemic crisis by 50 and >200% (P < 0.0001), respectively. The relationship between ammonia and hyperammonemic crisis risk seemed to be independent of treatment, age, urea cycle disorder subtype, dietary protein intake, or blood urea nitrogen. Fasting glutamine correlated weakly with daily ammonia exposure assessed as 24-hour area under the curve and was not a significant predictor of hyperammonemic crisis. CONCLUSION: Fasting ammonia correlates strongly and positively with daily ammonia exposure and with the risk and rate of hyperammonemic crises, suggesting that patients with urea cycle disorder may benefit from tight ammonia control.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hiperamonemia / Trastornos Innatos del Ciclo de la Urea / Glutamina / Amoníaco Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hiperamonemia / Trastornos Innatos del Ciclo de la Urea / Glutamina / Amoníaco Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos